tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
Yamamoto S and Kato R Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. 1994 J. Dermatol. Sci. pmid:7528050
Hossain M et al. Eosinophil viability-enhancing activity in mite-sensitive bronchial asthma. 1994 Intern. Med. pmid:7528071
Suzuki S FK506 and deoxyspergualin: experimental studies and clinical applications. 1994 Transpl. Immunol. pmid:7528087
Yli-Kauhaluoma J and Janda KD Twisted alpha-keto amides as transition-state analogues for acyl-transfer reactions: synthesis of the immunoconjugates. 1994 Bioorg. Med. Chem. pmid:7528089
Jindal RM et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. 1994 Transplantation pmid:7514317
Stan R et al. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. 1994 J. Biol. Chem. pmid:7528205
Haddy A and Rusnak F Overexpression and characterization of a recombinant form of rat calcineurin A. 1994 Biochem. Biophys. Res. Commun. pmid:7514397
Borel JF and Baumann G Molecular mechanisms of immunosuppressive agents. 1994 Bull. Mem. Acad. R. Med. Belg. pmid:7531051
Woerly G et al. Demonstration of ternary immunophilin-calcineurin complexes with the immunosuppressants cyclosporin and macrolide FK506. 1994 Biochem. Pharmacol. pmid:7514409
Whiting PH Acute and chronic nephrotoxicity associated with immunosuppressive drugs. 1994 Curr. Opin. Nephrol. Hypertens. pmid:7531104
Lauerma AI and Maibach HI Topical FK506--clinical potential or laboratory curiosity? 1994 Dermatology (Basel) pmid:7514460
Chen TS et al. Microbial transformation of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin (immunomycin) by Streptomyces sp. MA 6970 (ATCC No. 55281). 1994 J. Antibiot. pmid:7531195
Brillantes AB et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. 1994 Cell pmid:7514503
Tanaka K et al. Living related liver transplantation in children. 1994 Am. J. Surg. pmid:7517649
Yu L et al. NMR studies of the FK506 binding protein bound to a spin-labeled ascomycin analog. 1994 J Magn Reson B pmid:7517786
Aagaard-Tillery KM and Jelinek DF Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. 1994 Cell. Immunol. pmid:7517796
Furue M et al. Immunosuppressive effects of azelastine hydrochloride on contact hypersensitivity and T-cell proliferative response: a comparative study with FK-506. 1994 J. Invest. Dermatol. pmid:7517981
Suzuki S and Toledo-Pereyra LH Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. 1994 J. Surg. Res. pmid:7518017
D'Ambrosio R et al. Improved procedures for enzyme immunoassay of tacrolimus (FK506) in whole blood. 1994 Clin. Chem. pmid:7507007
Bäckman L et al. Chronic nephrotoxicity of FK 506 after liver transplantation. 1994 Transplant. Proc. pmid:7518159
Bäckman L et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. 1994 Transplant. Proc. pmid:7518160
Duncan JI Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. 1994 J. Invest. Dermatol. pmid:7507155
Engelbrecht ME et al. The effect of immunosuppressants on human leukocyte NADPH oxidase. 1994 Ann. N. Y. Acad. Sci. pmid:7518204
Reding R et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. 1994 Transplantation pmid:7507272
Zuany-Amorim C et al. Modulation by rm interferon-gamma and CD4+ T-lymphocytes of allergic eosinophil accumulation in the mice peritoneal cavity. 1994 Ann. N. Y. Acad. Sci. pmid:7518212
Sabatini DM et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. 1994 Cell pmid:7518356
Scantlebury VP et al. Pediatric kidney transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7509095
Oyanagui Y Nitric oxide- and hydrogen peroxide-mediated gene expression by glucocorticoids and FK506 in histamine paw edema of mice. 1994 Life Sci. pmid:7520521
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Yoshimura R et al. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7520610
Kitamura M et al. Clinical experience of FK 506 for renal allograft transplantation. 1994 Transplant. Proc. pmid:7520611
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Okamoto S et al. The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. 1994 J. Biol. Chem. pmid:7510691
Pai SY et al. Cross-linking CD28 leads to activation of 70-kDa S6 kinase. 1994 Eur. J. Immunol. pmid:7523138
Schmidt B et al. A homodimer represents an active species of the peptidyl-prolyl cis/trans isomerase FKBP25mem from Legionella pneumophila. 1994 FEBS Lett. pmid:7523184
Hakamata Y et al. Involvement of the brain type of ryanodine receptor in T-cell proliferation. 1994 FEBS Lett. pmid:7523185
Ahern GP et al. Single channel activity of the ryanodine receptor calcium release channel is modulated by FK-506. 1994 FEBS Lett. pmid:7523191
Clipstone NA et al. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. 1994 J. Biol. Chem. pmid:7523407
Lemster B et al. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. 1994 Autoimmunity pmid:7539635
Wakabayashi H et al. The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. 1994 Surg. Today pmid:7539646
Lepre CA et al. Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12. 1994 Biochemistry pmid:7524662
Yu L and Fesik SW pH titration of the histidine residues of cyclophilin and FK506 binding protein in the absence and presence of immunosuppressant ligands. 1994 Biochim. Biophys. Acta pmid:7524680
Papaccio G et al. The immunosuppressant FK506 inhibits the damage to mouse pancreatic islets induced by low dose streptozocin. 1994 Cell Tissue Res. pmid:7525068
Robertus J Structure-based drug design ten years on. 1994 Nat. Struct. Biol. pmid:7545074
Milan D et al. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. 1994 Cell pmid:7525078
Jiang H et al. The superior effect of the combination of FK 506 and deoxyspergualin on rat cardiac allograft survival. 1994 Transpl. Int. pmid:7527637
Devlin J et al. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group. 1994 Transpl. Int. pmid:11271328
Winkler M et al. The use of plasma levels for FK 506 dosing in liver-grafted patients. 1994 Transpl. Int. pmid:7527638
Otto G et al. Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271338
Stark JH et al. Sensitivity of baboon lymphocytes to cyclosporin A and FK 506: relative resistance of alloactivated cells to CyA. 1994 Transpl. Int. pmid:7527639
Wong P et al. FK 506 rescue therapy for intractable liver allograft rejection. 1994 Transpl. Int. pmid:11271339
Abdalla AH et al. FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. 1994 Transpl. Int. pmid:7527640
Mor E et al. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506. 1994 Transpl. Int. pmid:11271340
Cooper MH et al. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. 1994 Bone Marrow Transplant. pmid:7527689
Uemoto S et al. Long-term use of FK 506 in living related liver transplantation. 1994 Transpl. Int. pmid:11271341
Yasunami Y and Ikeda S Induction of donor specific unresponsiveness in rat islet allografts by intraportal grafting and FK506. 1994 Cell Transplant pmid:7512877
Mor E et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7513098
Lhoëst G et al. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. 1993 Sep-Oct Drug Metab. Dispos. pmid:7694828
Iwasaki K et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. 1993 Nov-Dec Drug Metab. Dispos. pmid:7507815
Fukuse T et al. Combined therapy with FK-506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508750
Morris RE New small molecule immunosuppressants for transplantation: review of essential concepts. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508752
Schreier MH Immunophilins and immunosuppression. 1993 Mar-Apr Clin. Exp. Rheumatol. pmid:7686830
Piekoszewski W et al. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. 1993 Jul-Aug Drug Metab. Dispos. pmid:7690698
Kobayashi J et al. A new rat infection-heart transplant model: effect of infection on graft survival studies. 1993 Jul-Aug J. Heart Lung Transplant. pmid:7690253
Cavaillé-Coll M and Mielach FA Choice of cyclophosphamide dose in baboon-to-human liver transplantation. 1993 Lancet pmid:7679768
Kobayashi M et al. HLA-DR matching effect in orthotopic liver transplantation under FK 506. 1993 Transplant. Proc. pmid:7679812
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Stephens J et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. 1993 Transplant. Proc. pmid:7680144
Bonet H et al. Survival of patients transplanted with alcoholic hepatitis plus cirrhosis as compared with those with cirrhosis alone. 1993 Transplant. Proc. pmid:7680145
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Yem AW et al. An active FK506-binding domain of 17,000 daltons is isolated following limited proteolysis of chicken thymus hsp56. 1993 Biochemistry pmid:7504525
Manev H et al. Macrolide antibiotics protect neurons in culture against the N-methyl-D-aspartate (NMDA) receptor-mediated toxicity of glutamate. 1993 Brain Res. pmid:7504570
Takahara S et al. [Blood level monitoring of FK506 on kidney transplant recipients]. 1993 Nippon Hinyokika Gakkai Zasshi pmid:7504758
Xu RX et al. 1H, 13C, and 15N assignments and secondary structure of the FK506 binding protein when bound to ascomycin. 1993 Biopolymers pmid:7682113
Tanaka N et al. Regulation of liver regeneration by interleukin-2 and its inhibitors: cyclosporine A and FK 506. 1993 Int. J. Immunopharmacol. pmid:7682200
Bruserud O and Pawelec G Cyclosporine A and FK506 show similar immunosuppressive effects on long-term in vitro T-cell proliferation. 1993 Int. J. Immunopharmacol. pmid:7682202
Fernandes JB et al. Comparative investigation of the effects of the immunosuppressants cyclosporine A, cyclosporine G, and FK-506 on platelet activation. 1993 Cell. Mol. Biol. Res. pmid:7507391
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Lemster B et al. FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions. 1993 Ann. N. Y. Acad. Sci. pmid:7509134
Tamura K et al. Inhibitory effect of FK 506 on autoimmune thyroid disease in the PVG rat. 1993 Ann. N. Y. Acad. Sci. pmid:7509135
Ochiai T et al. Combination of immunosuppressive drugs for organ transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509136
Natazuka T et al. FK506 and cyclosporin a regulate proliferation and proto-oncogene expression in HTLV-1-associated myelopathy/tropical-spastic-paraparesis-derived T cells. 1993 Int. J. Cancer pmid:7683633
Mukai H et al. FKBP12-FK506 complex inhibits phosphatase activity of two mammalian isoforms of calcineurin irrespective of their substrates or activation mechanisms. 1993 J. Biochem. pmid:7683641
Jachez B et al. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. 1993 Anticancer Drugs pmid:7683935
Hibbins M et al. Inhibition of PHA induced mononuclear cell proliferation by FK506 in combination with cyclosporine, methylprednisolone, 6-mercaptopurine and mycophenolic acid. 1993 Transpl. Immunol. pmid:7521736
Thomson AW et al. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. 1993 Transpl. Immunol. pmid:7521738
Calne RY et al. Intestinal transplant for recurring mesenteric desmoid tumour. 1993 Lancet pmid:7686241
Langer A et al. Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. 1993 Am. J. Pathol. pmid:7686346
Fujisawa T et al. Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation. 1993 Surg. Today pmid:7686416
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Kai N et al. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. 1993 Transplantation pmid:7682740
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Shaefer MS et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. 1993 Transplantation pmid:7689264
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Cetinkale O et al. The use of FK506 and skin allografting for the treatment of severe burns in an animal model. 1993 Br J Plast Surg pmid:7690295
Hom JT and Estridge T FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. 1993 Clin. Immunol. Immunopathol. pmid:7690315